Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.41 USD | +1.35% | -2.67% | -9.89% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.89% | 4.72B | |
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : , Capsida Collaborate on Gene-Edited Therapies for Amyotrophic Lateral Sclerosis, Friedreich's Ataxia